Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Pulmonology
Volume 2013 (2013), Article ID 308092, 3 pages
Case Report

Bilateral Vocal Cord Carcinoma in a Sarcoidosis Patient during Infliximab Therapy

1Centre of Interstitial Lung Diseases, Department of Pulmonology, St. Antonius Hospital, Koekoekslaan 1, 3435 CM Nieuwegein, The Netherlands
2Department of Otolaryngology, Head & Neck Surgery, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
3Division of Heart and Lungs, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands

Received 26 March 2013; Accepted 17 April 2013

Academic Editors: F. J. Aspa, D. Koksal, I. Lang, M. Lujan, H. Matsuoka, H. Niwa, M. Takao, and C. Y. Tu

Copyright © 2013 Adriane D. M. Vorselaars et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. P. Baughman and H. Nunes, “Therapy for sarcoidosis: evidence-based recommendations,” Expert Review of Clinical Immunology, vol. 8, no. 1, pp. 95–103, 2012. View at Google Scholar
  2. S. J. Bickston, G. R. Lichtenstein, K. O. Arseneau, R. B. Cohen, and F. Cominelli, “The relationship between infliximab treatment and lymphoma in Crohn's disease,” Gastroenterology, vol. 117, no. 6, pp. 1433–1437, 1999. View at Google Scholar · View at Scopus
  3. J. F. Colombel, E. V. Loftus Jr., W. J. Tremaine et al., “The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients,” Gastroenterology, vol. 126, no. 1, pp. 19–31, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. V. Van Hauwaert, S. Meers, G. Verhoef, S. Vermeire, P. Rutgeerts, and G. Van Assche, “Rectal non-Hodgkin's lymphoma in an infliximab treated patient with ulcerative colitis and primary sclerosing cholangitis,” Journal of Crohn's and Colitis, vol. 4, no. 6, pp. 683–686, 2010. View at Google Scholar
  5. P. Schultz, “Vocal fold cancer,” European Annals of Otorhinolaryngology, Head and Neck Diseases, vol. 128, no. 6, pp. 301–308, 2011. View at Google Scholar
  6. O. Laccourreye, S. Hans, D. Garcia, D. Veivers, D. Brasnu, and L. Laccourreye, “Metachronous second primary cancers after successful partial laryngectomy for invasive squamous cell carcinoma of the true vocal cord,” Annals of Otology, Rhinology and Laryngology, vol. 111, no. 3, pp. 204–209, 2002. View at Google Scholar · View at Scopus
  7. L. Biancone, A. Orlando, A. Kohn et al., “Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study,” Gut, vol. 55, no. 2, pp. 228–233, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. A. K. Wong, S. Kerkoutian, J. Said, H. Rashidi, and S. T. Pullarkat, “Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies,” Clinical Rheumatology, vol. 31, no. 4, pp. 631–636, 2011. View at Publisher · View at Google Scholar
  9. E. D. Dommasch, K. Abuabara, D. B. Shin, J. Nguyen, A. B. Troxel, and J. M. Gelfand, “The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials,” Journal of the American Academy of Dermatology, vol. 64, no. 6, pp. 1035–1050, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Askling, K. Fahrbach, B. Nordstrom, S. Ross, C. H. Schmid, and D. Symmons, “Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data,” Pharmacoepidemiology and Drug Safety, vol. 20, no. 2, pp. 119–130, 2011. View at Publisher · View at Google Scholar · View at Scopus